CRISPR Therapeutics AG

-0.13 (-0.12%)
Earnings Announcements

Crispr Therapeutics Reports Q1 2021 Financial Results

Published: 04/27/2021 21:49 GMT
CRISPR Therapeutics AG (CRSP) - Crispr Therapeutics Provides Business Update and Reports First Quarter 2021 Financial Results.
Crispr Therapeutics Ag - Total Collaboration Revenue Was $0.2 Million for Q1 of 2021 Compared to $0.2 Million for Q1 of 2020.
Crispr Therapeutics Ag - Qtrly Loss per Share $1.51.
Revenue is expected to be $226.51 Million
Adjusted EPS is expected to be $3.52

Next Quarter Revenue Guidance is expected to be $1.28 Million
Next Quarter EPS Guidance is expected to be -$1.05

More details on our Analysts Page.